Fagron NV (BR:FAGR) — Market Cap & Net Worth
Market Cap & Net Worth: Fagron NV (FAGR)
Fagron NV (BR:FAGR) has a market capitalization of $1.65 Billion (€1.41 Billion) as of May 2, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #6987 globally and #36 in its home market, demonstrating a 0.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fagron NV's stock price €24.00 by its total outstanding shares 73346728 (73.35 Million). Analyse Fagron NV operating cash flow efficiency to see how efficiently the company converts income to cash.
Fagron NV Market Cap History: 2015 to 2026
Fagron NV's market capitalization history from 2015 to 2026. Data shows growth from $653.69 Million to $2.06 Billion (3.61% CAGR).
Index Memberships
Fagron NV is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMX-Index
AMX
|
$85.25 Billion | 1.94% | #17 of 25 |
|
BEL Mid
BELM
|
$47.07 Billion | 3.51% | #11 of 28 |
|
BEL All Share
BSPT
|
$806.02 Billion | 0.20% | #41 of 108 |
Weight: Fagron NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fagron NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fagron NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.92x
Fagron NV's market cap is 1.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20.07x
Fagron NV's market cap is 20.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $776.65 Million | $421.84 Million | -$20.56 Million | 1.84x | N/A |
| 2017 | $912.73 Million | $436.93 Million | $46.66 Million | 2.09x | 19.56x |
| 2018 | $1.15 Billion | $471.68 Million | $42.49 Million | 2.44x | 27.06x |
| 2019 | $1.57 Billion | $534.70 Million | $55.69 Million | 2.93x | 28.14x |
| 2020 | $1.55 Billion | $555.97 Million | $59.60 Million | 2.78x | 25.95x |
| 2021 | $1.22 Billion | $573.81 Million | $61.00 Million | 2.12x | 19.93x |
| 2022 | $1.10 Billion | $683.88 Million | $69.61 Million | 1.61x | 15.85x |
| 2023 | $1.40 Billion | $762.99 Million | $70.55 Million | 1.84x | 19.87x |
| 2024 | $1.44 Billion | $871.96 Million | $80.55 Million | 1.65x | 17.84x |
| 2025 | $1.83 Billion | $952.17 Million | $91.02 Million | 1.92x | 20.07x |
Competitor Companies of FAGR by Market Capitalization
Companies near Fagron NV in the global market cap rankings as of May 2, 2026.
Key companies related to Fagron NV by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Fagron NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Fagron NV's market cap moved from $653.69 Million to $ 2.06 Billion, with a yearly change of 3.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.06 Billion | +12.68% |
| 2025 | €1.83 Billion | +27.09% |
| 2024 | €1.44 Billion | +2.53% |
| 2023 | €1.40 Billion | +27.02% |
| 2022 | €1.10 Billion | -9.25% |
| 2021 | €1.22 Billion | -21.37% |
| 2020 | €1.55 Billion | -1.31% |
| 2019 | €1.57 Billion | +36.30% |
| 2018 | €1.15 Billion | +25.96% |
| 2017 | €912.73 Million | +17.52% |
| 2016 | €776.65 Million | +18.81% |
| 2015 | €653.69 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Fagron NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.65 Billion USD |
| MoneyControl | $1.65 Billion USD |
| MarketWatch | $1.65 Billion USD |
| marketcap.company | $1.65 Billion USD |
| Reuters | $1.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more